A Review of Nonanesthetic Uses of Ketamine
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Ketamine, a nonselective NMDA receptor antagonist, is used widely in medicine as an anesthetic agent. However, ketamine’s mechanisms of action lead to widespread physiological effects, some of which are now coming to the forefront of research for the treatment of diverse medical disorders. This paper aims at reviewing recent data on key nonanesthetic uses of ketamine in the current literature. MEDLINE, CINAHL, and Google Scholar databases were queried to find articles related to ketamine in the treatment of depression, pain syndromes including acute pain, chronic pain, and headache, neurologic applications including neuroprotection and seizures, and alcohol and substance use disorders. It can be concluded that ketamine has a potential role in the treatment of all of these conditions. However, research in this area is still in its early stages, and larger studies are required to evaluate ketamine’s efficacy for nonanesthetic purposes in the general population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Blockade of NMDA Receptors and Apoptotic Neurodegeneration in the Developing Brain
Ikonomidou, C., Bosch, F., Miksa, M., Bittigau, P., Vöckler, J., Dikranian, K., Tenkova, T. I., Stefovska, V., Turski, L., & Olney, J. W. (1999) · Science · doi:10.1126/science.283.5398.70 · Cited by 2,055
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“Promisingly, efficacy from ketamine is seen in people with treatment-resistant depression, who have failed multiple antidepressant regimens [28, 29].”
BackgroundMurrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 2×
“Another drawback of ketamine is that, as a derivative of phencyclidine (PCP) [11], ketamine causes a transient increase in psychotomimetic symptoms [15, 41] and dissociative symptoms, though these return to baseline by 4 hours posttransfusion [41].”
BackgroundWilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525 · cited 1×
“5mg/ kg twice per week has been shown to achieve rapid-onset and sustained antidepressant effect for a 15-day period [30].”
BackgroundA Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480 · cited 1×
“For example, intranasal ketamine hydrochloride (50mg) has been shown to mediate an antidepressant effect, though the magnitude of the effect may be less than that of IV ketamine [35].”
BackgroundRandomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
McGirr, A., Berlim, M. T., Bond, D. J., Fleck, M. P., Yatham, L. N., & Lam, R. W. (2015) · Psychological Medicine · doi:10.1017/s0033291714001603 · Cited by 373
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246 · cited 1×
“0mg/kg) had a significantly higher rate of abstinence at two years [188].”
BackgroundKetamine Psychedelic Therapy (KPT): A Review of the Results of Ten Years of Research
Krupitsky, E. M., & Grinenko, A. Y. (1997) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1997.10400185 · Cited by 246
Aleksandrova, L. R., Phillips, A. G., & Wang, Y. T. (2017) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.160175 · Cited by 228 · cited 2×
“As a result of these drawbacks, many clinicians and researchers view IV ketamine infusions not as an end-all replacement for conventional antidepressants, but a promising new direction for antidepressant therapy that warrants further research and an effort to develop “ketamine-like” drugs that do not carry the side ef…”
BackgroundXu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv124 · Cited by 226 · cited 2×
“*is effect has been noted in both unipolar and bipolar depression [26], although effect duration may be shorter in patients with bipolar disorder [27].”
BackgroundHumble, S. R., Dalton, A. J., & Li, L. (2015) · European Journal of Pain · doi:10.1002/ejp.567 · Cited by 220
Dakwar, E., Nunes, E. V., Hart, C. L., Foltin, R. W., Mathew, S. J., Carpenter, K. M., Choi, C. J. “., Basaraba, C. N., Pavlicova, M., & Levin, F. R. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18101123 · Cited by 186
Orhurhu, V., Orhurhu, M. S., Bhatia, A., & Cohen, S. P. (2019) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000004185 · Cited by 179
Use of oral ketamine in chronic pain management: A review
Blonk, M. I., Koder, B. G., van den Bemt, P. M. L. A., & Huygen, F. J. P. M. (2010) · European Journal of Pain · doi:10.1016/j.ejpain.2009.09.005 · Cited by 168
MCNICOL, E. D., SCHUMANN, R., & HAROUTOUNIAN, S. (2014) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12377 · Cited by 167 · cited 1×
“Additionally, meta-analysis has also not shown intravenous and epidural ketamine to significantly reduce the rate of persistent postsurgical pain (PPSP) at three or six months [78].”
BackgroundKetamine for the treatment of addiction: evidence and potential mechanisms
Ivan Ezquerra-Romano, I., Lawn, W., Krupitsky, E., & Morgan, C. J. A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.01.017 · Cited by 163 · cited 1×
“In a study of 111 alcohol-dependent patients, relapse rates were significantly lower at one year in patients who received intramuscular ketamine [184], though this sentinel trial lacked both randomization and blinding [185].”
BackgroundKetamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131 · cited 1×
“For example, the possible antidepressant effects of other glutamatergic modulators, including riluzole, dextromethorphan, nitrous oxide, and GLYX-13 (rapastinel), are currently being examined [53].”
BackgroundKetamine can reduce harmful drinking by pharmacologically rewriting drinking memories
Das, R. K., Gale, G., Walsh, K., Hennessy, V. E., Iskandar, G., Mordecai, L. A., Brandner, B., Kindt, M., Curran, H. V., & Kamboj, S. K. (2019) · Nature Communications · doi:10.1038/s41467-019-13162-w · Cited by 122 · cited 1×
“However, the use of ketamine in alcohol and substance use disorders is complicated by its psychotogenic, dissociative properties and conventional IV administration route, which could pose particular challenges in patients with addiction or mental illnesses [189].”
BackgroundKetamine as a Potential Treatment for Suicidal Ideation: A Systematic Review of the Literature
Reinstatler, L., & Youssef, N. A. (2015) · Drugs in R&D · doi:10.1007/s40268-015-0081-0 · Cited by 120 · cited 1×
“Due to poor bioavailability resulting from high first-pass hepatic metabolism, ketamine is typically administered by injection, which is a drawback for medications that require ongoing dosing [21, 51].”
BackgroundFan, W., Yang, H., Sun, Y., Zhang, J., Li, G., Zheng, Y., & Liu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.13743 · Cited by 87 · cited 1×
“5mg/kg) has also demonstrated utility in treating acuteonset depression and suicidal ideation in one study of 39 newly diagnosed cancer patients [38].”
BackgroundGruner (2017) · doi:10.1016/j.neuroscience.2016.11.029 · Cited by 72 · cited 7×
“*is has been translated to clinical TBI research: in one study of 115 braininjured patients, ketamine administration (with a median dose of 200mg) was found to reduce the occurrence of the isoelectric spreading depolarizations that are seen in traumatized human cortex [139].”
BackgroundInfluentialLi, D.-J., Wang, F.-C., Chu, C.-S., Chen, T.-Y., Tang, C.-H., Yang, W.-C., Chow, P. C.-K., Wu, C.-K., Tseng, P.-T., & Lin, P.-Y. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.11.008 · Cited by 51 · cited 1×
“However, while meta-analysis of 16 articles with 346 patients has demonstrated superior treatment effect in patients with depression who receive ketamine in ECT over other anesthetics, these patients were also noted to have more side effects and longer recovery times [48].”
BackgroundKetamine for Depression: An Update
Murrough, J. W. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.005 · Cited by 20 · cited 2×
“*is clinical trial has largely been credited with launching the field of research into ketamine’s antidepressant effects [32].”
BackgroundMaintenance use of ketamine for treatment-resistant depression: an open-label pilot study.
Barenboim, I., & Lafer, B. (2018) · Revista Brasileira de Psiquiatria · doi:10.1590/1516-4446-2017-2380 · Cited by 8
Cited by
Van Amsterdam, J., & Van Den Brink, W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1949454 · Cited by 44
“In subanesthetic doses, ketamine is also applied for several acute and chronic pain syndromes [3], including”
BackgroundThe Possible Application of Ketamine in the Treatment of Depression in Alzheimer’s Disease
Mohammad Shehata, I., Masood, W., Nemr, N., Anderson, A., Bhusal, K., Edinoff, A. N., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022) · Neurology International · doi:10.3390/neurolint14020025 · Cited by 41
“Ketamine, a nonselective N-methyl-D-aspartate (NMDA) receptor antagonist, can mediate a wide range of pharmacological effects, including neuroprotection, anti-inflammatory and anticancer properties, multimodal analgesia, and treatment of depression, suicidal attempts, and status epilepticus [27].”
BackgroundJumaili, W. A., Trivedi, C., Chao, T., Kubosumi, A., & Jain, S. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2022.113804 · Cited by 29
Metadata
- Authors
- Pribish, A., Wood, N., & Kalava, A.
- Venue
- Anesthesiology Research and Practice
- Publisher
- Wiley
- Published
- 2020-04-01
- Volume
- 2020
- Pages
- 1-15
- ISSN
- 1687-6962 (ISSN-L)
- 1687-6970
- OpenAlex
- W3014706873
- Cited by
- 67
- References
- 30
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.